StemCell Therapy

FRAMINGHAM, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the 13th annual LD Micro Main Event investor conference. This investor conference will take place December 14-15, 2020, on the Sequire Virtual Events platform.

Excerpt from:
Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference

MONTREAL, Dec. 11, 2020 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that ECT-001 Cell Therapy has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) for use in urgent allogeneic haematopoietic stem cell transplants.

Go here to see the original:
ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy

MELBOURNE, Australia, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement (“Placement”), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate to invest in Australian based innovative healthcare technology and this investment will allow Cynata to significantly expand its clinical development pipeline and scale their operations in Australia. The Placement is being undertaken at an offer price of $0.70 for each new share and will be followed by a 1 for 15 non-renounceable entitlement offer at the same offer price as the Placement.

Link:
Cynata Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline

Company announcement – No. 59 / 2020

Read the original here:
Financial calendar for Zealand Pharma in 2021

Successfully completed listing on US Nasdaq and raised over $150 million during recent IPO and preceding crossover round

Read the original here:
Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Please read the full announcement in PDF

View original post here:
New sales reporting structure introduced. 2020 organic sales growth outlook now expected at 0%, from previously -2% to +2%

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors.

Read the original here:
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors

Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies

Read more:
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –

Read more from the original source:
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the...

CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes

See original here:
CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces new data on the efficacy and safety profile of long-term self-administration of nomacopan for treatment of patients with PNH.

Here is the original post:
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion...

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the third quarter ended September 30, 2020, as well as recent clinical progress.

Follow this link:
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its President and Chief Scientific Officer, Jude Samulski, PhD, has been honored as Triangle Business Journal’s (TBJ) 2020 Business Person of the Year.

Link:
AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal

NEW YORK, NY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has commenced the development of a Vegan, Cannabidiol (“CBD”) infused Pet Food Treat (“Pet Treat”).  The Company has contracted an industry expert to help with: formulations, specifications, designs, regulations, and certifications.  The Company’s aim is to commercially launch its proposed Pet Treat product, during March 2021.

More here:
Tauriga Sciences Inc. Commences Development of Vegan, CBD Infused Pet Treat

Exodus Effect CBD Oil is made of 100% natural ingredients that are specially formulated to alleviate pain. Find out yourself in our review. Exodus Effect CBD Oil is made of 100% natural ingredients that are specially formulated to alleviate pain. Find out yourself in our review.

See more here:
Exodus Effect Review - CBD Oil launched – Product Review by Mike Vaughn

TORONTO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will present at The Road Ahead, Preparation for 2021: MKM Partners Virtual Conference on Wednesday, December 16, 2020 at 12:30 p.m. EST.

Originally posted here:
Cronos Group Inc. to Present at the MKM Partners Virtual Conference

Signals momentum in addressing social equity, tax and banking reform, and the widespread adoption of cannabis in the U.S. Signals momentum in addressing social equity, tax and banking reform, and the widespread adoption of cannabis in the U.S.

Follow this link:
Golden Leaf Holdings Applauds the Historic Passing of the MORE Act

Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting

The rest is here:
Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA (naxitamab-gqgk) was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021.

The rest is here:
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

WILLIAMSVILLE, N.Y., Dec. 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it will be presenting at the 13th Annual LD Micro Main Event Conference on Monday, December 14, 2020, at 9:20 a.m. ET. James A. Mish, chief executive officer of 22nd Century Group, will be presenting to a live, virtual audience.

Read the original post:
22nd Century Group to Present at 13th Annual LD Micro Main Event Conference